Financhill
Sell
41

EKSO Quote, Financials, Valuation and Earnings

Last price:
$0.43
Seasonality move :
-13.02%
Day range:
$0.45 - $0.50
52-week range:
$0.34 - $1.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.54x
P/B ratio:
0.93x
Volume:
210.1K
Avg. volume:
132.7K
1-year change:
-63.63%
Market cap:
$11.8M
Revenue:
$17.9M
EPS (TTM):
-$0.57

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EKSO
Ekso Bionics Holdings
$4.6M -- 23.12% -- $9.00
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -35.77% $14.3929
QSI
Quantum-Si
$962.3K -$0.14 110.58% -- $3.38
VNRX
VolitionRX
$1.1M -$0.05 197.5% -46.88% $2.92
VTAK
Catheter Precision
$310K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.2M -$0.01 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EKSO
Ekso Bionics Holdings
$0.48 $9.00 $11.8M -- $0.00 0% 0.54x
CATX
Perspective Therapeutics
$2.4300 $14.3929 $179.9M -- $0.00 0% 15.73x
QSI
Quantum-Si
$1.20 $3.38 $219.8M -- $0.00 0% 56.19x
VNRX
VolitionRX
$0.50 $2.92 $49.2M -- $0.00 0% 35.08x
VTAK
Catheter Precision
$0.28 -- $2.6M 0.40x $0.00 0% 1.90x
XTNT
Xtant Medical Holdings
$0.50 $1.75 $69.9M -- $0.00 0% 0.57x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EKSO
Ekso Bionics Holdings
28.66% 0.633 37.69% 1.82x
CATX
Perspective Therapeutics
-- -1.032 -- --
QSI
Quantum-Si
-- 0.143 -- 11.60x
VNRX
VolitionRX
-28.76% 1.111 8.83% 0.19x
VTAK
Catheter Precision
12% -1.682 128.21% 0.53x
XTNT
Xtant Medical Holdings
44.29% -0.806 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EKSO
Ekso Bionics Holdings
$2.7M -$2.2M -60.09% -85.45% -65.89% -$1.5M
CATX
Perspective Therapeutics
-- -$20.9M -- -- -- -$41.2M
QSI
Quantum-Si
$610K -$30.7M -42.63% -42.63% -2573.57% -$24.3M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Ekso Bionics Holdings vs. Competitors

  • Which has Higher Returns EKSO or CATX?

    Perspective Therapeutics has a net margin of -67.05% compared to Ekso Bionics Holdings's net margin of --. Ekso Bionics Holdings's return on equity of -85.45% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EKSO
    Ekso Bionics Holdings
    53.32% -$0.14 $17.8M
    CATX
    Perspective Therapeutics
    -- -$0.61 --
  • What do Analysts Say About EKSO or CATX?

    Ekso Bionics Holdings has a consensus price target of $9.00, signalling upside risk potential of 949.54%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 492.3%. Given that Ekso Bionics Holdings has higher upside potential than Perspective Therapeutics, analysts believe Ekso Bionics Holdings is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    EKSO
    Ekso Bionics Holdings
    1 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is EKSO or CATX More Risky?

    Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock EKSO or CATX?

    Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EKSO or CATX?

    Ekso Bionics Holdings quarterly revenues are $5.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Ekso Bionics Holdings's net income of -$3.4M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.54x versus 15.73x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EKSO
    Ekso Bionics Holdings
    0.54x -- $5.1M -$3.4M
    CATX
    Perspective Therapeutics
    15.73x -- -- -$40.2M
  • Which has Higher Returns EKSO or QSI?

    Quantum-Si has a net margin of -67.05% compared to Ekso Bionics Holdings's net margin of -2778.61%. Ekso Bionics Holdings's return on equity of -85.45% beat Quantum-Si's return on equity of -42.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    EKSO
    Ekso Bionics Holdings
    53.32% -$0.14 $17.8M
    QSI
    Quantum-Si
    51.18% -$0.23 $215.4M
  • What do Analysts Say About EKSO or QSI?

    Ekso Bionics Holdings has a consensus price target of $9.00, signalling upside risk potential of 949.54%. On the other hand Quantum-Si has an analysts' consensus of $3.38 which suggests that it could grow by 181.94%. Given that Ekso Bionics Holdings has higher upside potential than Quantum-Si, analysts believe Ekso Bionics Holdings is more attractive than Quantum-Si.

    Company Buy Ratings Hold Ratings Sell Ratings
    EKSO
    Ekso Bionics Holdings
    1 0 0
    QSI
    Quantum-Si
    1 1 0
  • Is EKSO or QSI More Risky?

    Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison Quantum-Si has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock EKSO or QSI?

    Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quantum-Si offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. Quantum-Si pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EKSO or QSI?

    Ekso Bionics Holdings quarterly revenues are $5.1M, which are larger than Quantum-Si quarterly revenues of $1.2M. Ekso Bionics Holdings's net income of -$3.4M is higher than Quantum-Si's net income of -$33.1M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while Quantum-Si's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.54x versus 56.19x for Quantum-Si. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EKSO
    Ekso Bionics Holdings
    0.54x -- $5.1M -$3.4M
    QSI
    Quantum-Si
    56.19x -- $1.2M -$33.1M
  • Which has Higher Returns EKSO or VNRX?

    VolitionRX has a net margin of -67.05% compared to Ekso Bionics Holdings's net margin of -1226.82%. Ekso Bionics Holdings's return on equity of -85.45% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EKSO
    Ekso Bionics Holdings
    53.32% -$0.14 $17.8M
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About EKSO or VNRX?

    Ekso Bionics Holdings has a consensus price target of $9.00, signalling upside risk potential of 949.54%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 484.68%. Given that Ekso Bionics Holdings has higher upside potential than VolitionRX, analysts believe Ekso Bionics Holdings is more attractive than VolitionRX.

    Company Buy Ratings Hold Ratings Sell Ratings
    EKSO
    Ekso Bionics Holdings
    1 0 0
    VNRX
    VolitionRX
    2 1 0
  • Is EKSO or VNRX More Risky?

    Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

  • Which is a Better Dividend Stock EKSO or VNRX?

    Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EKSO or VNRX?

    Ekso Bionics Holdings quarterly revenues are $5.1M, which are larger than VolitionRX quarterly revenues of $474.5K. Ekso Bionics Holdings's net income of -$3.4M is higher than VolitionRX's net income of -$5.8M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.54x versus 35.08x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EKSO
    Ekso Bionics Holdings
    0.54x -- $5.1M -$3.4M
    VNRX
    VolitionRX
    35.08x -- $474.5K -$5.8M
  • Which has Higher Returns EKSO or VTAK?

    Catheter Precision has a net margin of -67.05% compared to Ekso Bionics Holdings's net margin of -4291.67%. Ekso Bionics Holdings's return on equity of -85.45% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    EKSO
    Ekso Bionics Holdings
    53.32% -$0.14 $17.8M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About EKSO or VTAK?

    Ekso Bionics Holdings has a consensus price target of $9.00, signalling upside risk potential of 949.54%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 622.28%. Given that Ekso Bionics Holdings has higher upside potential than Catheter Precision, analysts believe Ekso Bionics Holdings is more attractive than Catheter Precision.

    Company Buy Ratings Hold Ratings Sell Ratings
    EKSO
    Ekso Bionics Holdings
    1 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is EKSO or VTAK More Risky?

    Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.870, suggesting its less volatile than the S&P 500 by 187.02%.

  • Which is a Better Dividend Stock EKSO or VTAK?

    Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EKSO or VTAK?

    Ekso Bionics Holdings quarterly revenues are $5.1M, which are larger than Catheter Precision quarterly revenues of $96K. Ekso Bionics Holdings's net income of -$3.4M is higher than Catheter Precision's net income of -$4.1M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.54x versus 1.90x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EKSO
    Ekso Bionics Holdings
    0.54x -- $5.1M -$3.4M
    VTAK
    Catheter Precision
    1.90x 0.40x $96K -$4.1M
  • Which has Higher Returns EKSO or XTNT?

    Xtant Medical Holdings has a net margin of -67.05% compared to Ekso Bionics Holdings's net margin of -10.04%. Ekso Bionics Holdings's return on equity of -85.45% beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    EKSO
    Ekso Bionics Holdings
    53.32% -$0.14 $17.8M
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About EKSO or XTNT?

    Ekso Bionics Holdings has a consensus price target of $9.00, signalling upside risk potential of 949.54%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 248.33%. Given that Ekso Bionics Holdings has higher upside potential than Xtant Medical Holdings, analysts believe Ekso Bionics Holdings is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    EKSO
    Ekso Bionics Holdings
    1 0 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is EKSO or XTNT More Risky?

    Ekso Bionics Holdings has a beta of 1.094, which suggesting that the stock is 9.368% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

  • Which is a Better Dividend Stock EKSO or XTNT?

    Ekso Bionics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EKSO or XTNT?

    Ekso Bionics Holdings quarterly revenues are $5.1M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Ekso Bionics Holdings's net income of -$3.4M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Ekso Bionics Holdings's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings is 0.54x versus 0.57x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EKSO
    Ekso Bionics Holdings
    0.54x -- $5.1M -$3.4M
    XTNT
    Xtant Medical Holdings
    0.57x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Broadcom Stock a Millionaire Maker?
Is Broadcom Stock a Millionaire Maker?

Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…

Is Berkshire The Best Stock to Buy in a Bad Market?
Is Berkshire The Best Stock to Buy in a Bad Market?

Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…

Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?

The big picture trends in e‑commerce sales are clearly in…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
60
RGC alert for May 6

Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.

Buy
63
SKX alert for May 6

Skechers USA [SKX] is down 0.07% over the past day.

Sell
20
PTCT alert for May 6

PTC Therapeutics [PTCT] is down 11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock